N-Lorem: Difference between revisions
Content deleted Content added
Created new page. |
logo update |
||
| Line 4: | Line 4: | ||
| name = n-Lorem |
| name = n-Lorem |
||
| formation = January 8, 2020 |
| formation = January 8, 2020 |
||
| logo = N-lorem-logo.png |
|||
| headquarters = Carlsbad, California |
| headquarters = Carlsbad, California |
||
| leader_title = CEO |
| leader_title = CEO |
||
Revision as of 23:04, 6 October 2022
 | This article, N-Lorem, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
| File:N-lorem-logo.png | |
| Formation | January 8, 2020 |
|---|---|
| Headquarters | Carlsbad, California |
CEO | Stanley T. Crooke |
| Website | https://www.nlorem.org/ |
The n-Lorem Foundation is a non-profit organization based in Carlsbad, California, established to use personalized experimental antisense oligonucleotide medicines to treat nano-rare disease patients.[1] The nonprofit model allows the organization to provide nano-rare disease patients with personalized experimental medicines for free, for life.[2] [3]
History
The organization was founded by Stanley T. Crooke, former CEO of Ionis Pharmaceuticals and head of research at GlaxoSmithKline, in 2020.[4]
In 2022, n-Lorem teamed up with Columbia University to create Silence ALS, an initiative to develop personalized experimental therapies to treat patients with rare-genetic forms of ALS.[5]
References
- ^ "A devastating rare disease. A medicine created just for her son. Will it work?". San Diego Union-Tribune. 2021-09-16. Retrieved 2022-10-06.
- ^ "Drug development for ultra-rare diseases: What happens when N=1?". Clinical Trials Arena. 2022-04-21. Retrieved 2022-10-06.
- ^ "Local nonprofit helping patients with ultra-rare diseases". Del Mar Times. 2020-12-07. Retrieved 2022-10-06.
- ^ "With $4M in Funding, n-Lorem Foundation to Take on Rare Genetic Diseases". San Diego Business Journal. 2020-01-08. Retrieved 2022-10-06.
- ^ "New Initiative to Develop Personalized Therapies for People with Rare Genetic Forms of ALS". Columbia University Irving Medical Center. 2022-05-06. Retrieved 2022-10-06.